Targeting T-cell, B-cell & APC activation to treat chronic GvHD

Targeting T-cell, B-cell & APC activation to treat chronic GvHD

User Photo
VJHemOnc

1 year
383 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, talks about targeting T-cell, B-cell and APC activation to treat chronic GvHD, in order to derive alternative therapies to corticosteroid treatment. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.
Up Next Autoplay